{
    "clinical_study": {
        "@rank": "164761", 
        "arm_group": [
            {
                "arm_group_label": "Low dose LMWH", 
                "arm_group_type": "Active Comparator", 
                "description": "Fixed low dose low-molecular-weight heparin:\nFixed low dose nadroparin, or;\nFixed low dose enoxaparin, or;\nFixed low dose dalteparin, or;\nFixed low dose tinzaparin."
            }, 
            {
                "arm_group_label": "Intermediate dose LMWH", 
                "arm_group_type": "Active Comparator", 
                "description": "Intermediate dose low-molecular-weight heparin. Dosing is weight-adjusted according to the protocol.\nIntermediate dose nadroparin, or;\nIntermediate dose enoxaparin, or;\nIntermediate dose dalteparin, or;\nIntermediate dose tinzaparin."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a randomized-controlled open-label trial comparing two different doses of\n      low-molecular-weight heparin (LMWH) in pregnant patients with a history of previous venous\n      thromboembolism (VTE). Both doses are recommended doses in the 2012 guidelines of the\n      American College of Chest Physicians (ACCP), but it is not known which dose is more\n      efficacious in preventing recurrent venous thromboembolism in pregnancy.\n\n      Patients enter the study and will be randomized as soon as a home test confirms pregnancy.\n      LMWH will be administered until 6 weeks postpartum. Follow-up will continue until 3 months\n      postpartum. Patients will be recruited by their treating physician, either an obstetrician\n      or internist."
        }, 
        "brief_title": "Comparison of Low and Intermediate Dose Low-molecular-weight Heparin to Prevent Recurrent Venous Thromboembolism in Pregnancy", 
        "condition": [
            "Deep Venous Thrombosis", 
            "Pulmonary Embolism"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Embolism", 
                "Pulmonary Embolism", 
                "Thrombosis", 
                "Venous Thrombosis", 
                "Venous Thromboembolism"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age: 18 years or older, and;\n\n          -  Pregnancy confirmed by urinary pregnancy test, and;\n\n          -  Gestational age < 14 weeks, and;\n\n          -  Previous objectively confirmed VTE, either unprovoked, in the presence of use of oral\n             contraceptives or estrogen/progestagen use, or related to pregnancy or the postpartum\n             period, or minor risk factors (e.g. long distance travel, minor trauma).\n\n        Exclusion Criteria:\n\n          -  Previous VTE related to a major provoking risk factor (e.g. surgery, major trauma or\n             plaster cast immobilisation in the 3 months prior to VTE) as the sole risk factor,\n             or;\n\n          -  Indication for treatment with therapeutic dose anticoagulant therapy (e.g. treatment\n             of acute VTE; permanent use of therapeutic anticoagulants outside of pregnancy), or;\n\n          -  Inability to provide informed consent, or;\n\n          -  Any contraindication listed in the local labelling of LMWH."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "1000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01828697", 
            "org_study_id": "Highlow", 
            "secondary_id": [
                "2012-001505-24", 
                "NL40326.018.12", 
                "NTR3894"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Low dose LMWH", 
                "description": "Fixed low dose nadroparin: 2850 IU subcutaneously once-daily", 
                "intervention_name": "Low dose nadroparin", 
                "intervention_type": "Drug", 
                "other_name": [
                    "nadroparin", 
                    "Fraxiparin"
                ]
            }, 
            {
                "arm_group_label": "Intermediate dose LMWH", 
                "description": "Intermediate weight-adjusted dose nadroparin:\n< 50 kg: 3800 IU subcutaneously once-daily;\n50 to < 70 kg: 5700 IU subcutaneously once-daily;\n70 to < 100 kg: 7600 IU subcutaneously once-daily;\n100 kg or above: 9500 IU subcutaneously once-daily.", 
                "intervention_name": "Intermediate dose nadroparin", 
                "intervention_type": "Drug", 
                "other_name": [
                    "nadroparin", 
                    "Fraxiparin"
                ]
            }, 
            {
                "arm_group_label": "Low dose LMWH", 
                "description": "Fixed low dose enoxaparin: 40 mg subcutaneously once-daily", 
                "intervention_name": "Low dose enoxaparin", 
                "intervention_type": "Drug", 
                "other_name": [
                    "enoxaparin", 
                    "Clexane"
                ]
            }, 
            {
                "arm_group_label": "Intermediate dose LMWH", 
                "description": "Intermediate weight-adjusted dose enoxaparin:\n< 50 kg: 60 mg subcutaneously once-daily, or;\n50 kg to < 70 kg: 80 mg subcutaneously once-daily, or;\n70 kg to < 100 kg: 100 mg subcutaneously once-daily, or;\n100 kg or above: 120 mg subcutaneously once-daily.", 
                "intervention_name": "Intermediate dose enoxaparin", 
                "intervention_type": "Drug", 
                "other_name": [
                    "enoxaparin", 
                    "Clexane"
                ]
            }, 
            {
                "arm_group_label": "Low dose LMWH", 
                "description": "Fixed low dose dalteparin: 5,000 IU subcutaneously once-daily", 
                "intervention_name": "Low dose dalteparin", 
                "intervention_type": "Drug", 
                "other_name": [
                    "dalteparin", 
                    "Fragmin"
                ]
            }, 
            {
                "arm_group_label": "Intermediate dose LMWH", 
                "description": "Intermediate weight-adjusted dose dalteparin:\n< 50 kg: 7500 IU subcutaneously once-daily, or;\n50 kg to < 70 kg: 10000 IU subcutaneously once-daily, or;\n70 kg to < 100 kg: 12500 IU subcutaneously once-daily, or;\n100 kg or above: 15000 IU subcutaneously once-daily.", 
                "intervention_name": "Intermediate dose dalteparin", 
                "intervention_type": "Drug", 
                "other_name": [
                    "dalteparin", 
                    "Fragmin"
                ]
            }, 
            {
                "arm_group_label": "Low dose LMWH", 
                "description": "Fixed low dose tinzaparin: 4,500 IU subcutaneously once-daily", 
                "intervention_name": "Fixed low dose tinzaparin", 
                "intervention_type": "Drug", 
                "other_name": [
                    "tinzaparin", 
                    "Innohep"
                ]
            }, 
            {
                "arm_group_label": "Intermediate dose LMWH", 
                "description": "Intermediate weight-adjusted dose tinzaparin:\n< 50 kg: 3500 IU subcutaneously twice-daily, or;\n50 kg to < 70 kg: 10000 IU subcutaneously once-daily, or;\n70 kg to < 100 kg: 10000 IU subcutaneously once-daily, or;\n100 kg or above: 14000 IU subcutaneously once-daily.", 
                "intervention_name": "Intermediate dose tinzaparin", 
                "intervention_type": "Drug", 
                "other_name": [
                    "tinzaparin", 
                    "Innohep"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Calcium heparin", 
                "Heparin", 
                "Heparin, Low-Molecular-Weight", 
                "Dalteparin", 
                "Nadroparin", 
                "Enoxaparin", 
                "Tinzaparin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Low-molecular-weight heparin", 
            "Pregnancy", 
            "Venous thrombosis"
        ], 
        "lastchanged_date": "May 10, 2013", 
        "link": {
            "description": "Study website", 
            "url": "http://www.highlowstudy.org"
        }, 
        "location": {
            "contact": {
                "email": "s.m.bleker@amc.nl", 
                "last_name": "S. M. Bleker, MD"
            }, 
            "contact_backup": {
                "email": "n.vanes@amc.nl", 
                "last_name": "N. van Es, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Amsterdam", 
                    "country": "Netherlands", 
                    "state": "Noord-Holland", 
                    "zip": "1105 AZ"
                }, 
                "name": "Academic Medical Center"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Netherlands"
        }, 
        "number_of_arms": "2", 
        "official_title": "Low-molecular-weight Heparin to Prevent Recurrent VTE in Pregnancy: a Randomized Controlled Trial of Two Doses", 
        "other_outcome": [
            {
                "description": "Major bleeding is defined as overt bleeding and:\nAssociated with a fall in hemoglobin of 2 g/dL or more, or\nLeading to a transfusion of 2 or more units of packed red blood cells or whole blood, or\nOccurring in a critical site: intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retro-peritoneal, or\nContributing to death", 
                "measure": "Major bleeding", 
                "safety_issue": "Yes", 
                "time_frame": "During pregnancy until 3 months postpartum"
            }, 
            {
                "description": "See 'Major bleeding' for the definition.\nClinically relevant non-major bleeding is defined as overt bleeding not meeting the criteria for major bleeding but associated with medical intervention, unscheduled contact (visit or telephone call) with a physician, (temporary) cessation of study treatment, or associated with discomfort such as pain, or impairment of activities of daily life.\nHematuria if it is macroscopic, and either spontaneous or lasts for more than 24 hours after instrumentation (e.g. catheter placement or surgery) of the urogenital tract, or\nMacroscopic gastro-intestinal haemorrhage: at least one episode of melena/hematemesis, if clinically apparent, or\nRectal blood loss, if more than a few spots, or\nHemoptysis, if more than a few speckles in the sputum, or\nIntramuscular hematoma, or\nSubcutaneous hematoma if the size is larger than 25 cm2, or larger than 100 cm2 if provoked, or\nMultiple source bleeding", 
                "measure": "Composite of major bleeding and clinically relevant non-major bleeding", 
                "safety_issue": "Yes", 
                "time_frame": "During pregnancy until 3 months postpartum"
            }, 
            {
                "description": "Postpartum haemorrhage is defined as blood loss of more than 500 mL within 24 hours of delivery (WHO-criteria). Severe postpartum haemorrhage is defined as blood loss of more than 1000 mL within 24 hours of delivery.", 
                "measure": "Early postpartum hemorrhage", 
                "safety_issue": "Yes", 
                "time_frame": "Within 24 hours of delivery"
            }, 
            {
                "measure": "Blood transfusion < 6 weeks after delivery", 
                "safety_issue": "Yes", 
                "time_frame": "Within 6 weeks of delivery"
            }, 
            {
                "measure": "Blood transfusion < 24 hours postpartum", 
                "safety_issue": "Yes", 
                "time_frame": "Within 24 hours of delivery"
            }, 
            {
                "description": "Postpartum haemorrhage is defined as blood loss of more than 500 mL within 24 hours of delivery (WHO-criteria). Severe postpartum haemorrhage is defined as blood loss of more than 1000 mL within 24 hours of delivery.", 
                "measure": "Late postpartum hemorrhage", 
                "safety_issue": "Yes", 
                "time_frame": "From 24 hours postpartum to 6 weeks postpartum"
            }, 
            {
                "measure": "Mortality", 
                "safety_issue": "Yes", 
                "time_frame": "During pregnancy until 3 months postpartum"
            }, 
            {
                "description": "Minor bleeding is defined as all other overt bleeding episodes not meeting the criteria for major or clinically relevant bleeding or postpartum haemorrhage.", 
                "measure": "Minor bleeding", 
                "safety_issue": "Yes", 
                "time_frame": "During pregnancy until 3 months postpartum"
            }, 
            {
                "description": "e.g. itching, swelling, pain", 
                "measure": "Skin complications", 
                "safety_issue": "Yes", 
                "time_frame": "During pregnancy until 3 months postpartum"
            }, 
            {
                "measure": "Easy bruising", 
                "safety_issue": "Yes", 
                "time_frame": "During pregnancy until 3 months postpartum"
            }, 
            {
                "measure": "Necessity to switch to other LMWH", 
                "safety_issue": "Yes", 
                "time_frame": "During pregnancy until 6 weeks postpartum"
            }, 
            {
                "description": "Heparin-induced thrombocytopenia is defined according to the criteria of the ACCP guidelines.", 
                "measure": "Heparin-induced thrombocytopenia", 
                "safety_issue": "Yes", 
                "time_frame": "During pregnancy until 3 months postpartum"
            }, 
            {
                "measure": "Congenital anomalies or birth defects", 
                "safety_issue": "Yes", 
                "time_frame": "During pregnancy until 3 months postpartum"
            }
        ], 
        "overall_contact": {
            "email": "s.m.bleker@amc.nl", 
            "last_name": "S. M. Bleker, MD"
        }, 
        "overall_contact_backup": {
            "email": "n.vanes@amc.nl", 
            "last_name": "N. van Es, MD"
        }, 
        "overall_official": {
            "affiliation": "Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)", 
            "last_name": "S. Middeldorp, MD PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "All events of symptomatic deep venous thrombosis in subjects will be recorded from the the date of randomization up to 6 weeks postpartum.\nDefinition of symptomatic deep venous thrombosis (DVT):\nSuspected (recurrent) DVT with one of the following findings:\nIf there were no previous DVT investigations:\nAbnormal compression ultrasound (CUS),\nAn intraluminal filling defect on venography.\nIf there was a previous DVT investigation:\nAbnormal CUS where compression had been normal or, if non-compressible during screening, a substantial increase (4 mm or more) in diameter of the thrombus during full compression,\nAn extension of an intraluminal filling defect, or a new intraluminal filling defect or an extension of non-visualization of veins in the presence of a sudden cut-off on venography.", 
                "measure": "Symptomatic deep venous thrombosis", 
                "safety_issue": "No", 
                "time_frame": "From date of randomization up to 6 weeks postpartum"
            }, 
            {
                "description": "All events of symptomatic pulmonary embolism in subjects will be recorded from the the date of randomization up to 6 weeks postpartum.\nDefinition of symptomatic pulmonary embolism (PE):\nSuspected PE with one of the following findings:\nA (new) intraluminal filling defect in subsegmental or more proximal branches on spiral CT scan\nA (new) intraluminal filling defect or an extension of an existing defect or a new sudden cut-off of vessels more than 2.5 mm in diameter on the pulmonary angiogram\nA (new) perfusion defect of at least 75% of a segment with a local normal ventilation result (high-probability) on ventilation/perfusion lung scan (VPLS)", 
                "measure": "Symptomatic pulmonary embolism", 
                "safety_issue": "No", 
                "time_frame": "From date of randomization up to 6 weeks postpartum"
            }
        ], 
        "reference": [
            {
                "PMID": "10217099", 
                "citation": "Greer IA. Thrombosis in pregnancy: maternal and fetal issues. Lancet. 1999 Apr 10;353(9160):1258-65. Review."
            }, 
            {
                "PMID": "12130523", 
                "citation": "Pabinger I, Grafenhofer H, Kyrle PA, Quehenberger P, Mannhalter C, Lechner K, Kaider A. Temporary increase in the risk for recurrence during pregnancy in women with a history of venous thromboembolism. Blood. 2002 Aug 1;100(3):1060-2."
            }, 
            {
                "PMID": "18690344", 
                "citation": "White RH, Chan WS, Zhou H, Ginsberg JS. Recurrent venous thromboembolism after pregnancy-associated versus unprovoked thromboembolism. Thromb Haemost. 2008 Aug;100(2):246-52."
            }, 
            {
                "PMID": "22315276", 
                "citation": "Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO; American College of Chest Physicians. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb;141(2 Suppl):e691S-736S. doi: 10.1378/chest.11-2300."
            }, 
            {
                "PMID": "15811953", 
                "citation": "Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood. 2005 Jul 15;106(2):401-7. Epub 2005 Apr 5. Review."
            }, 
            {
                "PMID": "20464719", 
                "citation": "Tooher R, Gates S, Dowswell T, Davis LJ. Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period. Cochrane Database Syst Rev. 2010 May 12;(5):CD001689. doi: 10.1002/14651858.CD001689.pub2. Review."
            }, 
            {
                "PMID": "10365733", 
                "citation": "Sanson BJ, Lensing AW, Prins MH, Ginsberg JS, Barkagan ZS, Lavenne-Pardonge E, Brenner B, Dulitzky M, Nielsen JD, Boda Z, Turi S, Mac Gillavry MR, Hamuly\u00e1k K, Theunissen IM, Hunt BJ, B\u00fcller HR. Safety of low-molecular-weight heparin in pregnancy: a systematic review. Thromb Haemost. 1999 May;81(5):668-72. Review."
            }, 
            {
                "PMID": "11762651", 
                "citation": "Lepercq J, Conard J, Borel-Derlon A, Darmon JY, Boudignat O, Francoual C, Priollet P, Cohen C, Yvelin N, Schved JF, Tournaire M, Borg JY. Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies. BJOG. 2001 Nov;108(11):1134-40."
            }, 
            {
                "PMID": "15869590", 
                "citation": "Pabinger I, Grafenhofer H, Kaider A, Kyrle PA, Quehenberger P, Mannhalter C, Lechner K. Risk of pregnancy-associated recurrent venous thromboembolism in women with a history of venous thrombosis. J Thromb Haemost. 2005 May;3(5):949-54."
            }, 
            {
                "PMID": "21232006", 
                "citation": "Roeters van Lennep JE, Meijer E, Klumper FJ, Middeldorp JM, Bloemenkamp KW, Middeldorp S. Prophylaxis with low-dose low-molecular-weight heparin during pregnancy and postpartum: is it effective? J Thromb Haemost. 2011 Mar;9(3):473-80. doi: 10.1111/j.1538-7836.2011.04186.x."
            }, 
            {
                "PMID": "21314819", 
                "citation": "Lindqvist PG, Bremme K, Hellgren M; Working Group on Hemostatic Disorders (Hem-ARG), Swedish Society of Obstetrics and Gynecology. Efficacy of obstetric thromboprophylaxis and long-term risk of recurrence of venous thromboembolism. Acta Obstet Gynecol Scand. 2011 Jun;90(6):648-53. doi: 10.1111/j.1600-0412.2011.01098.x. Epub 2011 Apr 15."
            }, 
            {
                "PMID": "22102641", 
                "citation": "Roshani S, Cohn DM, Stehouwer AC, Wolf H, van der Post JA, B\u00fcller HR, Kamphuisen PW, Middeldorp S. Incidence of postpartum haemorrhage in women receiving therapeutic doses of low-molecular-weight heparin: results of a retrospective cohort study. BMJ Open. 2011 Nov 14;1(2):e000257. doi: 10.1136/bmjopen-2011-000257. Print 2011."
            }, 
            {
                "PMID": "20335572", 
                "citation": "Kaandorp SP, Goddijn M, van der Post JA, Hutten BA, Verhoeve HR, Hamuly\u00e1k K, Mol BW, Folkeringa N, Nahuis M, Papatsonis DN, B\u00fcller HR, van der Veen F, Middeldorp S. Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. N Engl J Med. 2010 Apr 29;362(17):1586-96. doi: 10.1056/NEJMoa1000641. Epub 2010 Mar 24."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01828697"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)", 
            "investigator_full_name": "S. Middeldorp", 
            "investigator_title": "prof.dr. S. Middeldorp", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "All events of symptomatic deep venous thrombosis in subjects will be recorded from the the date of randomization up to 3 months postpartum.\nDefinition of symptomatic deep venous thrombosis (DVT):\nSuspected (recurrent) DVT with one of the following findings:\nIf there were no previous DVT investigations:\nAbnormal compression ultrasound (CUS),\nAn intraluminal filling defect on venography.\nIf there was a previous DVT investigation:\nAbnormal CUS where compression had been normal or, if non-compressible during screening, a substantial increase (4 mm or more) in diameter of the thrombus during full compression,\nAn extension of an intraluminal filling defect, or a new intraluminal filling defect or an extension of non-visualization of veins in the presence of a sudden cut-off on venography.", 
                "measure": "Symptomatic deep venous thrombosis", 
                "safety_issue": "No", 
                "time_frame": "From date of randomization up to 3 months postpartum"
            }, 
            {
                "description": "All events of symptomatic pulmonary embolism in subjects will be recorded from the the date of randomization up to 3 months postpartum.\nDefinition of symptomatic pulmonary embolism (PE):\nSuspected PE with one of the following findings:\nA (new) intraluminal filling defect in subsegmental or more proximal branches on spiral CT scan\nA (new) intraluminal filling defect or an extension of an existing defect or a new sudden cut-off of vessels more than 2.5 mm in diameter on the pulmonary angiogram\nA (new) perfusion defect of at least 75% of a segment with a local normal ventilation result (high-probability) on ventilation/perfusion lung scan (VPLS)", 
                "measure": "Symptomatic pulmonary embolism", 
                "safety_issue": "No", 
                "time_frame": "From date of randomization up to 3 months postpartum"
            }
        ], 
        "source": "Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Netherlands Organisation for Scientific Research", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "GlaxoSmithKline", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}